NIA’s first ever Biotech Stock Suggestion: Citius Pharmaceuticals, Inc. (CTXR) continues to build HUGE momentum – rising another $0.46 or 9.9% yesterday to close at $5.10 per share, once again on very strong volume! CTXR is fast approaching its 200-day moving average of $5.76 per share, which is a key breakout point that when broken should send CTXR exploding towards the $9+ per share area that it needs to reach just for a $75 million market cap, which is the very minimum valuation that NIA believes CTXR deserves to immediately be trading at, considering that Mino-Lok appears to be perfectly positioned to potentially soon capture an unmet marketplace worth $750 million in the U.S. alone!
CTXR’s CEO Myron Holubiak wouldn’t have left his position as Chairman of BioScrip, Inc. (BIOS), a $700 million enterprise value company with $900 million in annual revenue – unless he believed CTXR will soon become a similar sized company! Prior to his role as Chairman of BIOS, Holubiak was the President of Roche Laboratories, Inc., the U.S. subsidiary of Roche Holding AG (RHHBY) the world’s third largest pharma with a market cap of $203 BILLION! He continues to serve as a Director of Assembly Biosciences (ASMB), which is now a $610 million market cap company!
CTXR’s Chairman Leonard Mazur has been a BIG buyer of CTXR stock in recent months, spending $1.77 million of his own money to personally accumulate an additional 432,400 shares!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from a third-party for covering CTXR of $20,000 cash. Never make investment decisions based on anything NIA says. This message is meant for informational and educational purposes only and does not provide investment advice.